Phase Ib/IIa Dose Escalation and Expansion Study of [??????Pb]Pb-ADVC001 in Metastatic Castration Resistant Prostate Cancer (TheraPb - Phase I/II Study)
Latest Information Update: 06 Feb 2025
At a glance
- Drugs 212 Pb ADVC 001 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man
- Acronyms TheraPb
- Sponsors AdvanCell
Most Recent Events
- 03 Feb 2025 According to AdvanCell media release, AdvanCell is currently enrolling patients for the highest dose cohort of its multi-center TheraPb Ph I/II dose escalation clinical trial of ADVC001 for metastatic prostate cancer
- 31 Jul 2024 Planned number of patients changed from 18 to 100.
- 31 Jul 2024 Planned End Date changed from 1 Jun 2024 to 31 Dec 2029.